We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Innoforce Pharmaceuticals, a biopharmaceutical innovation and partnership company, announced today the completion of a 625M CNY ($96M) Series A financing, which follows a 170M CNY ($24M) Pre-A financing completed in June 2020.
Innoforce and dMed have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.
Thermo Fisher Scientific and Innoforce have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing.